Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Rips Up Competition Rulebook To Allow Collaboration On Coronavirus

Medicines For Europe Welcomes European Commission’s Temporary Framework

Executive Summary

A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.

You may also be interested in...



Joined-Up EU Approach Is Key To Continuing COVID-19 Fight

At a Medicines for Europe webinar on learning lessons from the COVID-19 pandemic, a clear consensus emerged that a continued co-ordination between industry, regulators and the European Commission was key to both effectively address the current crisis and ensure a greater level of preparedness for similar challenges in future.

Coronavirus Update: More EU R&D Projects, A Potential New Vaccine & Making Sense Of The Data Deluge

In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national and EU level. 

Brand Industry Insists COVID-19 Relaxations Must Be Temporary

Speakers at a recent COVID-19 webinar discussed a number of issues related to the pandemic, including intellectual property protections, matching supply with demand, and what to do about excess manufacturing capacity once the crisis is over.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS142011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel